BR112023023270A2 - Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1 - Google Patents

Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1

Info

Publication number
BR112023023270A2
BR112023023270A2 BR112023023270A BR112023023270A BR112023023270A2 BR 112023023270 A2 BR112023023270 A2 BR 112023023270A2 BR 112023023270 A BR112023023270 A BR 112023023270A BR 112023023270 A BR112023023270 A BR 112023023270A BR 112023023270 A2 BR112023023270 A2 BR 112023023270A2
Authority
BR
Brazil
Prior art keywords
specifically binds
antibody
biespecific antibody
biespecific
present
Prior art date
Application number
BR112023023270A
Other languages
English (en)
Inventor
A-Ra Jeon
Heewook Shin
Tae Kim Heung
Seok Yoo Hyeon
Kook Kim Jeong
eun park Ji
Ji-Hye Choi
Jihyun Park
Jiyea Choi
Kwang Song Sun
Ho Kim Sung
Original Assignee
Immuneoncia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuneoncia Therapeutics Inc filed Critical Immuneoncia Therapeutics Inc
Publication of BR112023023270A2 publication Critical patent/BR112023023270A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Automatic Analysis And Handling Materials Therefor (AREA)

Abstract

a presente invenção se refere a um anticorpo biespecífico. o anticorpo biespecífico da presente invenção tendo alta afinidade de ligação a células tumorais que expressam pd-l1 e/ou cd47 e exibindo um excelente efeito antitumoral com um efeito colateral mínimo de hemaglutinação.
BR112023023270A 2021-05-07 2022-05-06 Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1 BR112023023270A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210059596 2021-05-07
PCT/KR2022/006521 WO2022235127A1 (ko) 2021-05-07 2022-05-06 Cd47 및 pd-l1에 특이적으로 결합하는 이중특이적 항체

Publications (1)

Publication Number Publication Date
BR112023023270A2 true BR112023023270A2 (pt) 2024-01-30

Family

ID=83932312

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023270A BR112023023270A2 (pt) 2021-05-07 2022-05-06 Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1

Country Status (12)

Country Link
US (1) US20240254233A1 (pt)
EP (1) EP4335872A1 (pt)
JP (1) JP2024518411A (pt)
KR (1) KR20220152172A (pt)
CN (1) CN117279948A (pt)
AU (1) AU2022270543A1 (pt)
BR (1) BR112023023270A2 (pt)
CA (1) CA3219221A1 (pt)
IL (1) IL308395A (pt)
MX (1) MX2023012995A (pt)
TW (1) TW202305006A (pt)
WO (1) WO2022235127A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118206663A (zh) * 2022-12-15 2024-06-18 中国科学院上海药物研究所 一种靶向cd47和pd-1的双特异性抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI719966B (zh) 2015-03-04 2021-03-01 美商索倫多醫療公司 結合ｃｄ４７之抗體治療劑
CN109715821B (zh) 2016-01-29 2022-09-06 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
EA039662B1 (ru) * 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
KR20200093639A (ko) * 2017-12-04 2020-08-05 북경한미약품 유한공사 천연 항체 구조-유사 헤테로다이머 형태의 항 pd-l1/항 cd47 이중특이성 항체 및 이의 제조
WO2019179434A1 (en) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/cd47 antibody molecules
BR112021026414A2 (pt) * 2019-06-25 2022-04-12 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
CN112745392B (zh) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 抗pd-l1/cd47双特异性抗体及其用途

Also Published As

Publication number Publication date
MX2023012995A (es) 2023-12-14
EP4335872A1 (en) 2024-03-13
AU2022270543A1 (en) 2023-11-30
CN117279948A (zh) 2023-12-22
CA3219221A1 (en) 2022-11-10
JP2024518411A (ja) 2024-05-01
KR20220152172A (ko) 2022-11-15
IL308395A (en) 2024-01-01
TW202305006A (zh) 2023-02-01
US20240254233A1 (en) 2024-08-01
WO2022235127A1 (ko) 2022-11-10

Similar Documents

Publication Publication Date Title
CO2020015084A2 (es) Anticuerpos anti-msr1 y métodos de uso de los mismos
BR112016026299A2 (pt) molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
CR11298A (es) Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano
CL2015002756A1 (es) Moléculas fc biespecíficas
EA201990781A1 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
BR112023023270A2 (pt) Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
BR112023016717A2 (pt) Anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47, molécula de ácido nucleico, e, uso do anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47
BR112022013878A2 (pt) Anticorpos que ligam integrina avb8 e utilizações dos mesmos
BR112021026890A2 (pt) Composições de anticorpo para interromper biofilmes
BR112023003511A2 (pt) Anticorpo biespecífico calr-cd3 mutante anticlivado e composição farmacêutica
BR112016007232A2 (pt) anticorpos anti-epcam e métodos de uso
BR112022016232A2 (pt) Proteínas biespecíficas anti-her2 manipuladas
BR112017018678A2 (pt) anticorpos de igg modificada que ligam o fator de crescimento de transformação beta1 com afinidade, avidez e especificidade altas
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
DOP2023000214A (es) Conjugados de anticuerpo anti-nectina-4 y exatecano
BR112023001061A2 (pt) Anticorpos antiabeta
BR112022000416A2 (pt) Anticorpo biespecífico, composição farmacêutica, conjugado, polinucleotídeo, célula e usos do anticorpo biespecífico
BR112023020574A2 (pt) Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos
BR112022012522A2 (pt) Proteínas de ligação de tgf-beta-rii
BR112023017556A2 (pt) Anticorpo contra nkp46 e aplicação do mesmo
CL2024000588A1 (es) Moléculas de unión a antígenos y usos de las mismas
BR112017004810A2 (pt) imunoensaio
CO2023007097A2 (es) Anticuerpos multiespecíficos y combinaciones de anticuerpos